Updated:
CSL Behring
CSL Behring is the biotherapeutics arm of CSL Limited, a global biotechnology company headquartered in Melbourne, Australia.
CSL Behring
CSL Behring is the biotherapeutics arm of CSL Limited, a global biotechnology company headquartered in Melbourne, Australia. The entity was established to discover, develop, and deliver high-quality medicines for people with rare and serious diseases. Its parent company, CSL, employs more than 32,000 people and operates in over 100 countries (per the firm, 2025). The firm invests across three strategic scientific platforms: plasma fractionation, recombinant protein technology, and cell and gene therapy. These platforms support a product portfolio targeting bleeding disorders, immune deficiencies, chronic inflammatory demyelinating polyneuropathy, hereditary angioedema, and Alpha 1 Antitrypsin Deficiency. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma, which supplies raw material for its therapies (per the firm). CSL Behring does not disclose AUM or investment professionals; it functions as an operating company rather than a traditional asset manager. The firm operates CSL Plasma, a vertically integrated plasma collection network with facilities in the United States and Europe. No recent structural or leadership changes have been publicly reported in the last 24 months (per firm website, 2025). CSL Behring's structural differentiator is its vertical integration from plasma collection to therapy manufacturing, a model that few competitors replicate. This approach ensures control over raw material supply and quality, distinguishing it from peer biotherapeutics firms that outsource plasma sourcing (per the firm).
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
King of Prussia
Corporate office
King of Prussia, PA, United States
Sector focus
Frequently asked questions
Who runs investment decisions at CSL Behring?
CSL Behring is a business unit of CSL Limited, and its investment and R&D decisions are directed by the CSL executive leadership team. The firm does not publicly name individual portfolio managers or a CIO for CSL Behring specifically; strategic direction comes from the parent company's board and management (per CSL's investor relations).
How does CSL Behring source proprietary deal flow?
CSL Behring primarily sources R&D opportunities internally via its three scientific platforms. Additionally, it engages in partnerships and acquisitions for drug candidates; examples include the acquisition of Vita Therapeutics and collaborations with academic institutions (per the firm's pipeline disclosures).
Is CSL Behring structured as a single family office or does it operate more like a venture firm?
CSL Behring is neither a family office nor a venture firm. It is an operating biotechnology business unit within the publicly traded CSL Limited (ASX: CSL). Its capital is deployed into internal R&D, manufacturing, and select external acquisitions, not into external fund commitments or direct investments in startups (per CSL annual report).
Does CSL Behring participate in fund commitments or only direct deals?
CSL Behring does not participate in third-party fund commitments. All capital deployment is direct, focusing on internal drug development, manufacturing scale-up, and strategic acquisitions that align with its therapeutic areas (per CSL filings).
What investment stages does CSL Behring typically target?
CSL Behring targets drug development from preclinical through commercial stages. It operates its own Discovery, Translational, and Clinical Development units, and may acquire clinical-stage assets or approved therapies. It does not invest in early-stage venture capital funds (per the firm).
Which sectors does CSL Behring explicitly avoid?
CSL Behring focuses exclusively on biotherapeutics for rare and serious diseases within immunology, hematology, cardiovascular and metabolic, respiratory, and transplant areas. It does not invest in other sectors such as digital health, medical devices, diagnostics, or industrial biotechnology (per firm website).
Where does the underlying wealth come from?
CSL Behring is not a family office; it is a business unit of CSL Limited, a publicly traded company. The wealth that funds its operations comes from CSL's revenues from product sales and capital markets (per CSL annual report).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: